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Abstract
Background: We evaluated data from isolates of nursing home (NH) patients sent to the Swiss centre for antibiotic
resistance (ANRESIS). We focussed on carbapenem-resistance (CR) among Gram-negative pathogens, extended-
spectrum cephalosporin-resistant (ESC-R) Escherichia coli/Klebsiella pneumoniae, methicillin-resistant Staphylococcus
aureus (MRSA), and glycopeptide-resistant enterococci (GRE).
Methods: NH patient isolates from 01/2007 to 10/2017 were extracted. Temporal trends in resistance were
described and risk factors associated with ESC-R and MRSA were assessed. For every administrative subdivision in
Switzerland (i.e. canton), we calculated a coverage rate, defined as number of beds of governmentally-supported
nursing homes, which sent ≥1 isolate in each 2014, 2015, and 2016, divided by the total number of supported
beds.
Results: We identified 16′804 samples from 9′940 patients. A majority of samples (12′040; 71.6%) originated from
the French/Italian speaking part of Switzerland. ESC-R E. coli increased from 5% (16/299) in 2007 to 22% (191/884) in
2017 (P < 0.01), whereas MRSA decreased from 34% (35/102) to 26% (21/81) (P < 0.01). Provenience from the
German (vs. French/Italian) speaking part of Switzerland was associated with decreased risk for ESC-R (OR 0.5, 95%
CI 0.4–0.7) and for MRSA (OR 0.1, 95% CI 0.1–0.2). CR among Pseudomonas aeruginosa was 10% (105/1096) and
showed an increasing trend over time; CR among Enterobacteriaceae (37/12′423, 0.3%) and GRE (5/1′273, 0.4%) were
uncommon. Overall coverage rate was 9% (range 0–58% per canton). There was a significant difference between
the French/Italian (median 13%, interquartile range [IQR] 4–43%) and the German speaking cantons (median 0%,
IQR 0–5%) (P = 0.02).
Conclusions: ESC-R among E. coli is emerging in Swiss NHs, whereas MRSA show a declining trend over time. A
minority of NHs are represented in ANRESIS, with a preponderance of institutions from the French/Italian speaking
regions. Efforts should be undertaken to improve resistance surveillance in this high-risk setting.
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Background
Long-term care facilities (LTCF) have been recognized
as an important reservoir for antibiotic resistant
pathogens [1–3]. In a recent point-prevalence study
from four different LTCF in Italy, the prevalence of
extended-spectrum beta-lactamase (ESBL)-carriage
was 57% and of methicillin-resistant Staphylococcus
aureus (MRSA) 17% [4]. Also in Italy, the prevalence
of carbapenemase-producing Enterobacteriaceae (CPE)
- one of the most concerning antibiotic resistance
threats - ranged from 1 to 6.3% [5]. Residence in an
LTCF has been shown to be a risk factor for carriage of
MRSA and glycopeptide-resistant enterococci (GRE) [6,
7]. Risk factors for resistant pathogens among nursing
home (NH) residents include previous antibiotic treat-
ment, invasive devices, age, open wounds, sharing a room
with a colonized patient, bedriddenness, or high degree of
disability [2, 4, 5, 8, 9].
In Switzerland, studies on antibiotic resistance from
NHs or other LTCFs have mostly focussed on MRSA and
have almost exclusively been generated in the Western
part of the country [10–13]. Previously published national
surveillance data on MRSA and extended-spectrum
cephalosporin resistant (ESC-R) Enterobacteriaceae from
Switzerland have not included data from LTCF [14, 15]. In
light of the alarming trends in antibiotic resistance from
LTCF in neighboring countries, we aimed to assess
temporal trends in the prevalence of antibiotic resistant
isolates from patients in Swiss NHs and to identify risk
factors associated with resistance.
Methods
Setting
This observational laboratory-based study was conducted
using the database from the Swiss antimicrobial resistance
surveillance network (ANRESIS) available since 2004 [16].
This database provides antibiotic resistance data for all
routinely collected microbiological samples from 20
clinical microbiology laboratories, distributed all over
Switzerland and representing at least 70% of annual
hospitalization days and 30% of all Swiss general practi-
tioners. For this analysis, we included all isolates sent to
ANRESIS from Swiss NHs.
Antimicrobial susceptibility testing was performed at
local laboratories according to Clinical and Laboratory
Standards Institute (CLSI) or European Committee on
Antimicrobial Susceptibility Testing (EUCAST) guide-
lines [17, 18]. Most of the participating laboratories
switched from CLSI to EUCAST breakpoints between
2011 and 2013. All laboratories are participating in at
least one external quality program out of the National
External Quality Assessment Service or the Swiss quality
control program from the Institute for Medical Micro-
biology, University of Zurich [19, 20].
Inclusion criteria and definitions
We extracted resistance data for all Enterobacteriaceae,
Pseudomonas aeruginosa, Acinetobacter spp., Staphylo-
coccus aureus and Enterococcus faecium/faecalis which
were sent to ANRESIS between January 2007 until
October 2017 with the patient label “long-term care”
and which originated from Swiss NHs. These pathogens
represent 81% of NH isolates sent to ANRESIS during
this time period. Although data were anonymous, every
patient possesses a unique identity number within their
institution, which was used to exclude repeat isolates
(i.e. same pathogen and resistance profile) from the same
patient in a specific calendar year. Each of the 26 admin-
istrative subdivisions in Switzerland (i.e. cantons) was
assigned to either the French/Italian (cantons of
Fribourg, Geneva, Jura, Ticino, Valais and Vaud), or the
German speaking part (all other cantons). Based on the
name of the institution linked to the isolate we distin-
guished the following types of institutions: i) govern-
mentally supported NHs according to publicly available
lists issued by the Federal Office of Public Health
(FOPH) [21]; and ii) not governmentally supported NHs.
For Enterobacteriaceae, Pseudomonas aeruginosa and
Acinetobacter spp., carbapenem-resistance (CR) was
studied. For Escherichia coli and Klebsiella pneumoniae,
ESC-R as well as co-resistances to quinolones, aminogly-
cosides, nitrofurantoin, and fosfomycin were evaluated.
Oxacillin- or cefoxitin-resistance among Staphylococcus
aureus was used as a proxy for methicillin-resistant S.
aureus (MRSA). Glycopeptide-resistant Enterococcus fae-
calis/faecium (GRE) were also studied. Resistance to a
particular substance was defined as either intermediate
or resistant susceptibility test according to the individual
laboratories. Group resistance (e.g. glycopeptide, carba-
penem, aminoglycoside or quinolone resistance) was
defined as resistance or intermediate susceptibility to at
least one antibiotic of the respective group, ESC-R was
defined as resistance or intermediate susceptibility to at
least one antibiotic tested out of 3rd or 4th generation
cephalosporins.
Calculation of coverage rate
For every canton, we estimated the coverage rate of
governmentally supported NHs sending microbiology
isolates to ANRESIS. This was achieved by dividing the
number of beds represented by institutions in the
dataset who sent at least one isolate to ANRESIS in
2014, 2015, and 2016 by the total number of beds. The
number of supported beds was collected from publicly
available lists of the FOPH for the year 2016 [21, 22].
Data analysis and statistics
Categorical variables were reported as frequencies and pro-
portions, continuous variables as median with interquartile
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range (IQR). For dichotomous variables, Chi-square or
Fisher-exact tests were used, as appropriate. For compari-
son of coverage rates between geographic regions, the
Mann-Whitney-U was used. For each type of resistance,
the proportion of pathogens with the resistance trait (as %
of the total number of isolates reported and tested for the
respective key antibiotic) was analysed over time. Linear
regression analysis was used to estimate the association be-
tween resistance (independent variable) and year of sur-
veillance (dependent variable).
For ESC-R and MRSA, univariable and multivariable
logistic regression analysis with generalized estimating
equation (GEE) were performed to assess factors inde-
pendently associated with resistance. The following
co-variables were assessed: Patient age group (i.e. < 70,
70–85, > 85 years), sex, geographical region (i.e. French/
Italian, German), and site of sample collection (i.e. uro-
genital, skin, respiratory, other). Co-variables were en-
tered into multivariable analysis in case of a P value< 0.1
in univariable analysis. Two-sided P values ≤0.05 were
considered statistically significant. SAS Studio was used
for all statistical analyses.
Sensitivity analysis
To eliminate potential selection bias, a sensitivity analysis
was performed assessing resistance time trends exclusively
for NHs which sent microbiological isolates every year
between 2007 and 2017 (only for ESC-R and MRSA, as
the sample sizes for the other pathogens were too small).
Results
Data sources
After removal of duplicates, we identified 19′189 tested
pathogens from 16′804 samples and 9′940 patients. Of
the samples, 14′663 (87.3%) were from governmentally
funded NHs and 2′141 (12.7%) from non-funded NHs.
A majority of samples (12′040; 71.6%) originated from
the French/Italian and 4′764 (28.4%) from the German
speaking part of Switzerland.
ESC-R for E. Coli and K. pneumoniae
We identified 8′607 E. coli and 1′825 K. pneumoniae
isolates, mostly from the urinary tract (97% of E. coli
and 94% of K. pneumoniae). ESC-R was more common
among E. coli (14.1%) compared to K. pneumoniae
(7.0%). From 2007 to 2017, ESC-R E. coli increased from
5.4% (16/299) to 21.6% (191/884) (P < 0.0001) (Fig. 1a).
A similar but less pronounced increase from 1.6 to 7.8%
was observed for ESC-R K. pneumoniae (P < 0.0001). In
multivariable analysis, isolates originating from the Ger-
man speaking part of Switzerland (vs. French/Italian; OR
0.5, 95% CI 0.4–0.7) were less likely, and those from
men (vs. women; OR 1.6, 95% CI 1.2–2.1) more likely to
exhibit ESC-R (Table 1). Co-resistances were more
frequent in the ESC-R group, for both E. coli and K.
pneumoniae. For ESC-R E. coli, resistance to fluoroqui-
nolones was 75%, whereas resistance to aminoglycosides,
nitrofurantoin and fosfomycin were 25.7, 8.8 and 6.8%,
respectively (Fig. 2).
Carbapenem-resistance (CR)
Among Enterobacteriaceae, 37 of 12′423 tested isolates
(0.3%) were resistant to carbapenems. CR was more
common among patients less than 70 years of age (P =
0.01) and those from the French/Italian speaking regions
(P = 0.01); no time trend was observed (P = 0.14). Among
P. aeruginosa, 105 of 1′096 isolates (9.6%) showed CR,
with an increasing trend from 2007 (2%) to 2016 (8%)
(P = 0.0001). Non-urogenital isolates (thereof 68% skin
and 25% respiratory isolates) more frequently exhibited
CR (12.3%) than urogenital samples (8.4%, P = 0.04).
Among 83 tested Acinetobacter spp. isolates, none
exhibited CR. Additional file 1: Table S1 gives an over-
view on the isolates included in this analysis.
Methicillin-resistant Staphylococcus aureus
Among 1′482 isolates of S. aureus, 556 (37.5%) were
resistant to methicillin. Prevalence decreased over time
from 34.3% (35/102) in 2007 to 25.9% (21/81) in 2017
(P = 0.004) (Fig. 1a). Geographical provenance was the
only factor associated with methicillin-resistance in mul-
tivariable analysis, with isolates from the German part
being less commonly resistant than those from French/
Italian speaking parts of Switzerland (OR 0.1, 95% CI
0.1–0.2, P < 0.0001) (Table 2).
Glycopeptide-resistant enterococci
GR among enterococci was uncommon (5/1′273; 0.4%).
Due to the small number of resistant isolates, no further
analyses were performed. Additional file 1: Table S1 gives
an overview on the isolates included in this analysis.
Sensitivity analysis
Considering only institutions participating in ANRESIS
from 2007 throughout to 2017, the same time trends
could be observed for ESC-R (15 institutions, 1′555
isolates) with resistance increasing from 4.2% in 2007 to
21.7% in 2017 (P < 0.0001). For MRSA (14 institutions,
201 isolates), the high proportion of resistance persisted
from 2007 (42.4%) to 2017 (60%) (P = 0.61).
Coverage of governmentally supported institutions
Considering 11′584 samples from governmentally
funded NHs which sent samples throughout 2014 to
2016, the national coverage rate of supported NH beds
was 9%. Whereas some cantons did not provide any
isolates to ANRESIS, others had coverage rates of up to
58%, again with a significant difference between the
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French/Italian (median 13%, IQR 4–43%) and the
German (median 0%, IQR 0–5%) speaking part of the
country (P = 0.02). Additional file 1: Figure S1 shows the
coverage rate for every canton.
Discussion
In this analysis of national resistance data from Swiss
NHs, we show that ESC-R have been clearly increasing
between 2007 and 2017 reaching 22% among E. coli
isolates, whereas the proportion of MRSA among S.
aureus isolates is declining. The nationwide collection
of NH isolates and the inclusion of data over more
than a decade are notable strengths of this study and
increase its validity and significance.
The analysis of the available resistance data shows a
significant increase of ESC-R among E. coli and K.
pneumoniae. These findings mirror the increase of
ESC-R observed in an ANRESIS analysis of inpatient and
outpatient isolates from Swiss acute care institutions [15].
According to the ANRESIS database, the proportion of
ESC-R among invasive E. coli acute care isolates for the
year 2016 was 9%, compared to 18% in our data [23]. This
supports the notion of NHs being a high-risk setting for
ESBL-producing pathogens. In contrast to the study by
Kronenberg et al., where isolates from the German part of
Switzerland exhibited slightly more frequently ESC-R, we
found - on the contrary - a significantly higher resistance
rate among isolates originating from French/Italian
speaking regions [15]. Indeed, particularly for resistant
Gram-negative pathogens, the countries bordering
Switzerland in the South (Italy) and in the West (France)
have reported a high ESBL prevalence of 58% among NH
residents and 28% among patients on geriatric wards,
respectively [4, 24]. In Germany and Austria, somewhat
lower ESBL carriage rates of 18 and 13% have been
reported from these settings [25, 26]. In our study, male
Fig. 1 Resistance trends (in %, y-axis) of ESC-R Escherichia coli (a) and of methicillin-resistant Staphylococcus aureus (b) in Swiss nursing homes
between 2007 and 2017 using a linear regression model (including 95% confidence interval in light blue)
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sex was clearly associated with ESC-R, which has also
been described for patients in Switzerland not residing in
NHs [15]. Although several other studies have docu-
mented an association of male sex with carriage of or
infection with ESBL-producing organisms [27–29], others
found female sex to be associated with ESBL-carriage
or infection [30–32]. It has been suggested that these
conflicting findings might be due to differences in
antibiotic prescribing practices for women with uncompli-
cated cystitis [27]. Interestingly, the proportion of
ESC-R E. coli with co-resistance to fluoroquinolones
was high at 75% in our study. Whether this high pro-
portion is due to the dissemination of the frequently
fluroroquinolone-resistant ST131 E. coli clone in
Swiss NHs (as shown for other countries) should be
further evaluated [33–35]. Based on our resistance
data and in accordance with national antibiotic treat-
ment guidelines, nitrofurantoin and fosfomycin re-
main reasonable options for the empirical treatment
of NH patients, at least for uncomplicated urinary
tract infections [36].
We found the proportion of MRSA among S. aureus
isolates to be declining between 2007 and 2017. This is
in line with national acute care resistance data, but also
with two point-prevalence studies performed in 2010/11
and 2015 among residents of NH in the canton of Vaud
[10, 13, 14]. In addition, samples from the German
speaking part of Switzerland less commonly exhibited
methicillin-resistance than those from French/Italian
speaking parts, which also has been shown for the Swiss
acute care setting [14]. Nevertheless, these data - and
particularly the high resistance rates of over 50% in 2009
- should be interpreted with caution because i) the abso-
lute number of S. aureus isolates was relatively small (N
= 1′482), and ii) the decreasing trend over time could
not be confirmed in the sensitivity analysis.
CR among P. aeruginosa from NH residents is increas-
ing in all geographic regions in Switzerland. Potential ex-
planations include the increasing use of carbapenems
and/or the change from CLSI to EUCAST breakpoints,
which has been shown to lead to decreased susceptibility
rates, in particular for P. aeruginosa tested for carbapen-
ems [37–39]. The proportion of CR among Enterobacte-
riaceae and Acinetobacter spp. as well as glycopeptide
resistance among enterococci is negligible in Swiss NHs.
Nevertheless, especially for CR among Enterobacteria-
ceae, regular surveillance is indicated in light of their
emergence in geographically close regions such as
Northern Italy, where LTCF are known high-risk settings
for these pathogens.
Only 9% of governmentally-supported NH beds in
Switzerland are represented in ANRESIS and from
Table 1 Patient characteristics and univariable and multivariable logistic regression using generalized estimating equation for
evaluation of risk factors for ESC-R in patients with Escherichia coli and Klebsiella pneumoniae isolates from Swiss NHs between 2007
and 2016
ESC-S ESC-R Univariable Multivariable
n = 9′093 n = 1′339 Row %a OR (95% CI) P value OR (95% CI) P value
Sex 0.03 0.003
Female 7′436 1′063 12.5 ref. ref.
Male 1′657 276 14.3 1.4 (1.0–1.9) 1.6 (1.2–2.1)
Age in years
< 70 713 110 13.4 ref. –
70–85 5′479 799 12.7 0.9 (0.7–1.2) 0.60
> 85 2′901 430 12.9 1.0 (0.8–1.2) 0.74
Region
French/Italian speaking 6′407 1′037 13.9 ref. ref.
German speaking 2′686 302 10.1 0.5 (0.4–0.7) <.0001 0.5 (0.4–0.7) <.0001
Site
Urogenital 8′788 1′286 12.8 ref. –
Other 305 53 14.8 1.4 (0.7–2.5) 0.34
Species
E. coli 7′396 1′211 14.1 ref. ref.
K. pneumoniae 1′697 128 7.0 0.2 (0.1–0.3) <.0001 0.2 (0.1–0.3) <.0001
Abbreviations: ESC-R Extended-spectrum beta-lactam resistant, ESC-S Extended-spectrum beta-lactam susceptible, NH Nursing Home, OR Odds Ratio, CI Confidence
Interval, ref Reference
Significant P values are in bold and non-significant ones (P ≥ 0.05) are not in bold
aESC-R/(ESC-S + ESC-R)
Kohler et al. Antimicrobial Resistance and Infection Control  (2018) 7:88 Page 5 of 9
many cantons in the German speaking part of
Switzerland, LTCF isolates are lacking completely. We
can only speculate on the reasons for these gaps in
the reporting system. One potential reason is that NH
residents are often treated by their family physicians,
and therefore the samples are not attributed to the
institution, but to general physicians. By only includ-
ing samples which could be unambiguously ascribed
to NHs, we also decreased the number of samples
and the statistical power of our analysis. However, the
credibility and validity of our results are strengthened
through this approach.
Our study has several limitations. First, the overrepre-
sentation of the French/Italian speaking part of the
country hampers the generalizability of our analysis.
Still, we believe that the available data are of interest to
public health authorities, clinical microbiologists, hos-
pital epidemiologists, and also to clinicians in care of
NH patients. Second, comparability of laboratory data
across different institutions over more than a decade can
be debated. As mentioned above, several laboratories
have switched from CLSI to EUCAST breakpoints
during the observed time period. Also, we cannot ex-
clude inconsistencies in testing for particular antibiotic
Fig. 2 Co-resistances of Escherichia coli and Klebsiella pneumoniae isolates from Swiss nursing home residents between 2007 and 2016, by
resistance to extended-spectrum cephalosporins (ESC), including 95% confidence intervals
Kohler et al. Antimicrobial Resistance and Infection Control  (2018) 7:88 Page 6 of 9
substances such as fosfomycin, which requires the de-
termination of the minimal inhibitory concentration
in the presence of glucose-6-phosphate. Third, we
cannot fully exclude the possibility that collection
practices changed during the observed time period or
between geographical regions in Switzerland, which
might have confounded our results. Fourth, it remains
debatable to what extent ESC-R can be used as a
proxy for ESBL-production. However, in the 2016
antibiotic resistance report of the European Centre
for Disease Prevention and Control, 89% of ESC-R E.
coli were ESBL-producers [40]. Fifth, our approach of
calculating a coverage rate for every canton can be
discussed. Because the number of samples sent per
institution was not considered in the calculation, large
institutions sending few samples to ANRESIS will be
overrepresented compared to small institutions send-
ing many samples. Sixth, because certain pathogens
such as streptococci are not included in our analysis,
the coverage rate might be slightly underestimated.
However, we found that the isolates in our study
represent 81% of all NH isolates, which allows to
reasonably estimate the coverage rate.
Conclusions
The prevalence of ESC-R E. coli and K. pneumoniae
among Swiss NHs has clearly been increasing over
the last decade. In this analysis of mostly urinary
samples, nitrofurantoin and fosfomycin retained high
susceptibility rates against E. coli, even for ESC-R
isolates. The proportion of MRSA among S. aureus
seems to be declining. Efforts should be undertaken
to increase the coverage of NHs samples in the na-
tional resistance database ANRESIS, especially in the
German speaking parts of Switzerland.
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canton. (DOCX 101 kb)
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Table 2 Patient characteristics and results of univariable and multivariable logistic regression using generalized estimating equation
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2017
MSSA MRSA Univariable Multivariable
n = 926 n = 556 Row %a OR (95% CI) P value OR (95% CI) P value
Sex
Female 542 298 35.5 ref. ref.
Male 384 258 40.2 1.4 (0.9–2.2) 0.11 1.6 (1.0–2.5) 0.06
Age in years
< 70 133 57 30.0 ref. ref.
70–85 563 361 39.1 1.5 (1.1–2.2) 0.02 1.3 (0.9–1.9) 0.13
> 85 230 138 37.5 1.5 (1.0–2.2) 0.04 1.3 (0.8–1.9) 0.27
Region
French/Italian speaking 697 498 41.7 ref. ref.
German speaking 229 58 20.2 0.1 (0.1–0.2) < 0.0001 0.1 (0.1–0.2) < 0.0001
Sampling site
Urogenital 259 174 40.2 ref. ref.
Skin 492 294 37.4 0.9 (0.7–1.2) 0.44 0.9 (0.7–1.1) 0.20
Other 175 88 33.5 0.8 (0.5–1.1) 0.09 0.7 (0.5–1.0) 0.06
Abbreviations: MSSA Methicillin-susceptible Staphylococcus aureus, MRSA Methicillin-resistant Staphylococcus aureus, OR Odds Ratio, CI Confidence Interval
Significant P values are in bold and non-significant ones (P ≥ 0.05) are not in bold
aESC-R/(ESC-S + ESC-R)
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